Fully Funded Glaucoma Study for Artelo's ART27.13 Expands Pipeline, Mitigates Cash Burn
ARTL has more than doubled off its 52-week low of $3.15 on elevated volume (14× avg).
Summary
Artelo Biosciences has announced a definitive investigator-initiated study agreement to evaluate its drug candidate, ART27.13, in patients with glaucoma or ocular hypertension. Crucially, this clinical study is fully funded by third parties, Glaucoma UK and the HSC R&D Division, which is a significant positive for the micro-cap company, especially given its recent 'going concern' disclosure and low cash position from the 10-K and subsequent 8-K filings. This agreement expands ART27.13's potential therapeutic profile beyond its lead indication in cancer-related anorexia into a new, large market (glaucoma affects over 80 million people worldwide) without incurring additional R&D costs for Artelo. The first patient enrollment is anticipated in Q2 2026, providing a near-term catalyst. This capital-efficient strategy could enhance the value of ART27.13 and offers a new avenue for growth for the company.
At the time of this announcement, ARTL was trading at $6.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $3.15 to $85.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.